CRISPR-created Animal Models: The Technical Lowdown

Creating reproducible animal models for long-term studies can often be problematic due to the complexity of the genetic modification(s) required. Suboptimal design strategies compound the challenges by generating undesired genotypic or phenotypic results. CRISPR-Cas9 or zinc-finger nuclease (ZFN)-based technologies can circumvent the challenges of complex genetic alterations due to the precision inherent to these methods. Beyond these methods, which result in constitutive changes to the genome, other genome editing methods are available; these include humanization, conditional knockout, point mutation, and reporter tagging. The sponsor of this webinar, Horizon Discovery, offers custom in vivo model generation services. Join us to learn how to go from concept to F1 in five months.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Excipients and Formulation Assessments of Complex Generic Products

The goal of this webinar is to provide an overview of the regulatory framework, scientific concepts, product-specific challenges, and best practices related to development of complex generic drug products.
Watch Now

2023 Pharma Digital Transformation

Digitalization in the pharmaceutical industry is a pervasive and persistent phenomenon that rapidly changes how patients engage with pharma and purchase drugs. The pandemic has just accelerated the changes which already began before
Watch Now

How To Develop Fully Compliant Electronic Drug Delivery Devices

business-review

Using electronics today is a part of our daily lives. It is almost impossible to imagine how the world would be without electronics. The healthcare industry is not an exception to this. The drive towards having connected healthcare has become a well-established facet of current drug delivery device development, the overwhelming potential benefits has led to an explosion of development projects aiming to create connected device.
Watch Now

The top 5 cybersecurity threats to pharma for 2022

It's no secret that pharma companies are struggling to protect themselves from cyberattacks amid the pandemic. Data breaches are costing the sector around US$5m a year, while one in 10 pharma companies are at risk of a ransomware attack, exacerbated by a perfect storm of shifting to remote working, increased growth, antiquated OT systems and a lack of cybersecurity skills.
Watch Now

Spotlight

resources